[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"brain-vascular-function\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:brain-vascular-function":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,66,89,118],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":38,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":65},"100625406","long-term-effects-of-walnut-consumption-on-brain-function-100625406",false,"NCT07422220","Long-Term Effects of Walnut Consumption on Brain Function","Long-Term Effects of Walnut Consumption on Brain Function in Men and Women With Abdominal Obesity","WalBrain","Inclusion Criteria:\n\n* Men and women, aged between 45-75 years\n* Women postmenopausal: two or more years after last menstruation\n* Waist circumference of ≥102 cm for men and ≥88 cm for women (abdominal obesity)\n* Fasting plasma glucose \\\u003C 7.0 mmol\u002FL\n* Fasting serum total cholesterol \\\u003C 8.0 mmol\u002FL\n* Fasting serum triacylglycerol \\\u003C 4.5 mmol\u002FL\n* Systolic blood pressure \\\u003C 160 mmHg and diastolic blood pressure \\\u003C 100 mmHg\n* Stable body weight (weight gain or loss \\\u003C 3 kg in the past three months)\n* Willingness to give up being a blood donor from 8 weeks before the start of the study, during the study and for 4 weeks after completion of the study\n* No difficult venipuncture as evidenced during the screening visit\n\nExclusion Criteria:\n\n* Allergy or intolerance to walnuts\n* Left-handedness (effects on brain function differ between left- and right-handed adults)\n* Current smoker, or smoking cessation \\\u003C 12 months\n* Diabetic patients\n* Familial hypercholesterolemia\n* Abuse of drugs\n* More than 3 alcoholic consumptions per day\n* Use of products or dietary supplements (e.g., dietary fiber or antioxidant dietary supplements (vitamin C and E), fish or seaweed oil capsules) known to interfere with the main outcomes as judged by the principal investigators\n* Use of medication to treat blood pressure, lipid, or glucose metabolism\n* Use of an investigational product within another biomedical intervention trial within the previous 1-month\n* Severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease, inflammatory bowel diseases, auto inflammatory diseases, and rheumatoid arthritis\n* Active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebrovascular accident\n* Contra-indications for MRI imaging (e.g., pacemaker, surgical clips\u002Fmaterial in body, metal splinter in eye, claustrophobia)",true,"ALL","45 Years","75 Years",{"count":22,"type":23},55,"ESTIMATED","INTERVENTIONAL",[26],"NA","Rationale: Healthy foods, including mixed nuts, may improve brain function, which is essential for cognitive and metabolic health, and may contribute to improved food intake regulation. It is therefore important to investigate the specific effects of walnuts on cerebral blood flow responses before and after intranasal insulin administration, as well as their associated functional benefits. The investigators hypothesize that long-term walnut consumption improves vascular function and insulin-sensitivity in the brain, thereby enhancing cognitive performance and appetite control in abdominally obese men and women. Objective: The primary objectives are to investigate in abdominally obese adults the effects of 24-week walnut consumption on (regional) vascular function and insulin-sensitivity in the brain, while the investigators will also assess changes in cognitive performance and appetite-related brain reward activity (secondary objectives). Cerebral blood flow responses before (brain vascular function) and after the administration of intranasal insulin spray (brain insulin-sensitivity) will be quantified by the non-invasive gold standard magnetic resonance imaging (MRI)-perfusion method Arterial Spin Labeling (ASL). Study design: This intervention study will have a randomized, controlled parallel design. The total study duration will be 24 weeks. Study population: Fifty-five abdominally obese men and (postmenopausal) women (aged 45-75 years) without a history of cardiovascular diseases or complaints will participate. This study population is expected to have a decreased cerebral blood flow at baseline and are also at increased risk of cognitive impairment, allowing for improvement by the intervention. Intervention: Study participants will receive daily 50 g (about 15% of energy) of raw walnuts (walnut intervention) or no walnuts (control intervention) for 24 weeks. Main study parameters\u002Fendpoints: At baseline and after 24 weeks (follow-up), participants will visit the research facilities for assessments. The primary endpoint is the difference in the cerebral blood flow response before and after intranasal insulin administration between the walnut and control intervention. Cognitive performance will be assessed, while the investigators will also focus on appetite-related brain reward activity (secondary outcomes).",[29,30,31,32,33,34,35,36,37],"Healthy","Brain Insulin Sensitivity","Cerebral Blood Flow","Brain Vascular Function","Satiety and Food Intake","Food Reward","Cognitive Performance","Abdominal Obesity","Cognitive Decline",[39,40,41,42,43,44,45,46,47,48,49,50,51,52],"Walnuts","Juglans","Brain vascular function","Brain insulin sensitivity","Satiety","Food reward mechanisms","Cognitive performance","Abdominal obesity","Cognitive decline","pCASL MRI","fMRI","CANTAB","Intranasal insulin","Food cues","NOT_YET_RECRUITING","2026-02-18",{"date":56,"type":57},"2026-02-19","ACTUAL",{"date":59,"type":23},"2026-02",{"date":61,"type":23},"2027-08",{"name":63,"class":64},"Maastricht University Medical Center","OTHER",1,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":17,"sex":18,"minAge":73,"maxAge":20,"enrollmentInfo":74,"targetDuration":4,"studyType":24,"phases":76,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":65},"100620260","high-dairy-food-patterns-and-gut-brain-axis-100620260","NCT07355309","High-Dairy Food Patterns and Gut-Brain Axis","Longer-term Effects of High-dairy Food Patterns on the Gut-brain Axis in Adults With Overweight or Obesity","Inclusion Criteria:\n\n* Men and postmenopausal women (≥ 2 years since last menstruation);\n* Aged between 40-75 years;\n* BMI between 25-35 kg\u002Fm2 (overweight or obese);\n* Low-to-moderate habitual dairy consumption (≤ 3 servings\u002Fday);\n* Fasting serum total cholesterol \\\u003C 8.0 mmol\u002FL;\n* Fasting serum triacylglycerol \\\u003C 4.5 mmol\u002FL;\n* Fasting plasma glucose \\\u003C 7.0 mmol\u002FL;\n* Systolic blood pressure \\\u003C 160 mmHg and diastolic blood pressure \\\u003C 100 mmHg;\n* Stable body weight (weight gain or loss \\\u003C 3 kg in the past three months).\n\nExclusion Criteria:\n\n* Left-handedness;\n* Milk protein allergy or lactose intolerance;\n* Current smoker, or smoking cessation \\\u003C 12 months;\n* Familial hypercholesterolemia;\n* Abuse of drugs;\n* Alcoholic intake \\>3 standard drinks\u002Fday;\n* Use of medications, food products or dietary supplements affecting glucose, lipid, or blood pressure regulation, gut microbiota or mental or neurological function, judged by the principal investigator;\n* Use of antibiotics within the previous month;\n* Use of other biomedical investigational products within the previous month;\n* Participation in another clinical trial within the past month;\n* Severe medical conditions including type 2 diabetes, epilepsy, asthma, kidney failure, COPD, inflammatory bowel disease, autoimmune diseases, or rheumatoid arthritis;\n* History of cardiovascular events (e.g., heart attack, stroke) or active cardiovascular disease;\n* Contra-indications for MRI imaging (e.g. pacemaker, metal implants, claustrophobia);\n* Willing to donate blood starting from 8 weeks before the study begins, throughout the study, and for 4 weeks after its inclusion;\n* Difficult to venipuncture as evidenced during the screening visit.","40 Years",{"count":75,"type":23},40,[26],"Disturbances in brain insulin sensitivity are associated not only with obesity and type 2 diabetes, but also with brain aging and cognitive decline. Longitudinal studies suggest that dietary patterns, particularly those high in dairy intake, may impact brain function via the gut-brain axis. Indeed, dairy foods are known to modulate gut microbiota and may, through this pathway, not only improve brain insulin sensitivity and cognitive performance, but also mental health and appetite regulation. However, underlying mechanisms remain largely unexplored. The primary objective of this study is to evaluate, in older adults with overweight or obesity, the effects of a high-dairy food pattern (4-5 daily servings of (butter)milk, cheese, yogurt, or cottage cheese) compared to a low-dairy food pattern (≤1 serving daily) on (regional) brain vascular function and insulin sensitivity. These outcomes will be quantified using the non-invasive MRI perfusion technique Arterial Spin Labeling (ASL), which assesses cerebral blood flow (CBF) in response to intranasal insulin, a validated physiological marker of brain insulin sensitivity. Secondary objectives include changes in cognitive performance (via the CANTAB neuropsychological test battery), gut microbiota composition (via shotgun metagenomic analysis of fecal samples), and appetite-related brain reward activity (via BOLD-fMRI with food cues). Exploratory analyses include conventional cardiometabolic risk markers (blood pressure, lipid and glucose metabolism), and perceivable (consumer) benefits.",[30,32,31,35,79,80],"Appetite Control","Gut Microbiota","2026-01-12",{"date":83,"type":57},"2026-01-21",{"date":85,"type":23},"2025-12-22",{"date":87,"type":23},"2027-04-01",{"name":63,"class":64},{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":17,"sex":18,"minAge":96,"maxAge":20,"enrollmentInfo":97,"targetDuration":4,"studyType":24,"phases":99,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":65},"100606609","effects-of-wild-blueberry-consumption-on-brain-function-in-elderly-100606609","NCT07177781","Effects of Wild Blueberry Consumption on Brain Function in Elderly","Longer-term Effects of Wild Blueberry Consumption on Brain Function in Older Men and Women","Inclusion Criteria:\n\n* Men and women, aged between 60-75 years\n* BMI between 25-35 kg\u002Fm2 (overweight or obese)\n* Fasting plasma glucose \\\u003C 7.0 mmol\u002FL\n* Fasting serum total cholesterol \\\u003C 8.0 mmol\u002FL\n* Fasting serum triacylglycerol \\\u003C 4.5 mmol\u002FL\n* Systolic blood pressure \\\u003C 160 mmHg and diastolic blood pressure \\\u003C 100 mmHg\n* Stable body weight (weight gain or loss \\\u003C 3 kg in the past three months)\n* Willingness to give up being a blood donor from 8 weeks before the start of the study, during the study and for 4 weeks after completion of the study.\n* No difficult venipuncture as evidences during the screening visit.\n\nExclusion Criteria:\n\n* Allergy or intolerance to berries\n* Left-handedness\n* Current smoker, or smoking cessation \\\u003C 12 months\n* Diabetic patients\n* Familial hypercholesterolemia\n* Abuse of drugs\n* More than 3 alcoholic consumptions per day\n* Use of products or dietary supplements known to interfere with the main outcomes as judged by the principal investigators\n* Use medication to treat blood pressure, lipid, or glucose metabolism\n* Use of an investigational product within another biomedical intervention trial within the previous 1-month\n* Severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease, inflammatory bowel diseases, auto inflammatory diseases, and rheumatoid arthritis.\n* Active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebrovascular accident.\n* Contra-indications for MRI imaging (e.g., pacemaker, surgical clips\u002Fmaterial in body, metal splinter in eye, claustrophobia)","60 Years",{"count":98,"type":23},36,[26],"Impaired brain vascular function precedes the development of reduced cognitive performance, while brain insulin-resistance is associated with cognitive decline. Evidence from epidemiological studies has already suggested beneficial effects of wild blueberry consumption on cognitive performance. However, underlying mechanisms have not yet been established, while well-controlled trials on longer-term effects of wild blueberries on cognitive performance are highly needed. This study hypothesizes that longer-term wild blueberry intake improves (regional) brain vascular function and insulin-sensitivity, thereby improving cognitive performance in older men and women. The primary objectives are to investigate in older adults the effect wild blueberry consumption on (regional) vascular function and insulin-sensitivity in the brain, and to focus on changes in cognitive performance as assessed with the CANTAB neuropsychological test battery (i.e., secondary objective). Cerebral blood flow responses before (brain vascular function) and after the administration of intranasal insulin spray (brain insulin-sensitivity) will be non-invasively quantified by the non-invasive gold standard magnetic resonance imaging (MRI)- perfusion method Arterial Spin Labeling (ASL).",[102,32,31],"Brain Insulin-sensitivity",[45,104,41,105,106,107,108],"Brain insulin-resistance","Cerebral blood flow","Wild blueberry","Brain insulin-sensitivity","Anthocyanin","RECRUITING","2025-09-10",{"date":112,"type":57},"2025-09-17",{"date":114,"type":57},"2024-12-05",{"date":116,"type":23},"2026-08-31",{"name":63,"class":64},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":17,"sex":18,"minAge":96,"maxAge":20,"enrollmentInfo":125,"targetDuration":4,"studyType":24,"phases":127,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":65},"100597342","effects-of-protein-supplementation-on-brain-function-100597342","NCT07057245","Effects of Protein Supplementation on Brain Function","Effects of Daily Protein Supplementation on Brain Function in Older Adults With Overweight or Obesity","Inclusion Criteria:\n\n* Men and women, aged between 60-75 years (older adults)\n* BMI between 25-35 kg\u002Fm2 (overweight or obese)\n* Fasting plasma glucose \\\u003C 7.0 mmol\u002FL\n* Fasting serum total cholesterol \\\u003C 8.0 mmol\u002FL\n* Fasting serum triacylglycerol \\\u003C 4.5 mmol\u002FL\n* Systolic blood pressure \\\u003C 160 mmHg and diastolic blood pressure \\\u003C 100 mmHg\n* Stable body weight (weight gain or loss \\\u003C 3 kg in the past three months)\n* Willingness to give up being a blood donor from 8 weeks before the start of the study, during the study and for 4 weeks after completion of the study\n* No difficult venipuncture as evidenced during the screening visit\n\nExclusion Criteria:\n\n* Intolerant to milk products or fava bean allergy\n* Vegetarians\n* Left-handedness\n* Current smoker, or smoking cessation \\\u003C 12 months\n* Diabetic patients\n* Familial hypercholesterolemia\n* Abuse of drugs\n* More than 3 alcoholic consumptions per day\n* Use of products or dietary supplements known to interfere with the main outcomes as judged by the principal investigators\n* Use medication to treat blood pressure, lipid, or glucose metabolism\n* Use of an investigational product within another biomedical intervention trial within the previous 1-month\n* Severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease, inflammatory bowel diseases, auto inflammatory diseases, and rheumatoid arthritis\n* Active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebrovascular accident\n* Contra-indications for MRI imaging (e.g., pacemaker, surgical clips\u002Fmaterial in body, metal splinter in eye, claustrophobia)",{"count":126,"type":23},25,[26],"Protein-rich foods may improve brain insulin-sensitivity, which is important for cognitive and metabolic health, and may also translate into an improved food intake regulation. It is therefore pertinent to delineate the effects of plant-derived proteins, which are a more sustainable alternative to animal-derived proteins, on brain insulin-sensitivity and related functional benefits. The hypothesis is that daily plant-derived or animal-derived protein supplementation improves brain vascular function and insulin-sensitivity, thereby improving cognitive performance and appetite control in overweight or obese older men and women.\n\nThe primary objective is to investigate in overweight or obese older adults the effect of daily protein supplementation for two weeks with either a plant-derived protein or an animal-derived protein on vascular function and insulin-sensitivity in the brain, while changes in cognitive performance and appetite-related brain reward activity will also be evaluated (secondary study objectives). Cerebral blood flow responses before (brain vascular function) and after the administration of intranasal insulin spray (brain insulin-sensitivity) will be quantified by the gold standard magnetic resonance imaging (MRI)-perfusion method Arterial Spin Labeling (ASL).",[32,130,43,31,30],"Cognitive Function","2025-06-30",{"date":133,"type":57},"2025-07-09",{"date":135,"type":23},"2025-07-02",{"date":137,"type":23},"2025-12-31",{"name":63,"class":64}]